PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18577377-2 2008 The earliest known ChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of AD patients. Physostigmine 43-56 butyrylcholinesterase Homo sapiens 19-22 20047897-2 2010 The aim of this study was to examine the analgesic and antihyperalgesic properties of the cholinesterase inhibitor physostigmine and the opioid alfentanil, alone and in combination, in an experimental pain model in humans. Physostigmine 115-128 butyrylcholinesterase Homo sapiens 90-104 20144867-1 2010 A series of physostigmine analogues were prepared and evaluated for cholinesterase inhibition activities, including acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Physostigmine 12-25 butyrylcholinesterase Homo sapiens 68-82 19583746-0 2009 The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: a randomized study. Physostigmine 29-42 butyrylcholinesterase Homo sapiens 4-18 19416629-3 2009 M(1)-muscarinic agonist McN-A-343 and the cholinesterase inhibitor physostigmine also elicited relaxation responses in the coaxial bioassay besides acetylcholine. Physostigmine 67-80 butyrylcholinesterase Homo sapiens 42-56 21204339-18 2009 Studies with the centrally acting cholinesterase inhibitor physostigmine demonstrated consistent but partial reversal of scopolamine-induced memory deficits [11,12]. Physostigmine 59-72 butyrylcholinesterase Homo sapiens 34-48 17950687-1 2008 The inhibition of horse serum butyrylcholinesterase (EC 3.1.1.8) by three carbamates (eserine, neostigmine, and rivastigmine) was studied by flow microcalorimetry at 37 degrees C in Tris buffer (pH 7.5). Physostigmine 86-93 butyrylcholinesterase Homo sapiens 30-51 18077465-2 2008 We hypothesised that neural responses in AD during visuo-attentional processing would be impaired relative to controls, yet partially susceptible to improvement with the cholinesterase inhibitor physostigmine. Physostigmine 195-208 butyrylcholinesterase Homo sapiens 170-184 17655781-3 2008 The primary aim of this randomized controlled study was to assess the efficiency of the cholinesterase-inhibitor physostigmine in these children and to identify adverse effects. Physostigmine 113-126 butyrylcholinesterase Homo sapiens 88-102 14766981-5 2004 In this study, increasing central nervous cholinergic activation during SWS-rich sleep by posttrial infusion of 0.75 mg of the cholinesterase inhibitor physostigmine completely blocked SWS-related consolidation of declarative memories for word pairs in human subjects. Physostigmine 152-165 butyrylcholinesterase Homo sapiens 127-141 16278840-3 2006 Validation of the putative positron emission tomography method included regional distribution, positive correlation with age, and attenuation by the nonselective cholinesterase inhibitor physostigmine, but no attenuation by the AChE-selective inhibitor donepezil. Physostigmine 187-200 butyrylcholinesterase Homo sapiens 162-176 16958557-39 2006 The converse, giving atropine to treat poisoning with cholinesterase inhibitors, of which physostigmine was the first, has endured more consistently and remains standard practice today. Physostigmine 90-103 butyrylcholinesterase Homo sapiens 54-68 15974893-2 2005 Novel drug design studies have focused on the classical ChE inhibitor, (-)-physostigmine, producing alterations in chemical composition and three-dimensional structure, which may offer an improved therapeutic index. Physostigmine 75-88 butyrylcholinesterase Homo sapiens 56-59 17658455-0 2007 Intraoral stimulation of salivary secretion with the cholinesterase inhibitor physostigmine as a mouth spray: a pilot study in healthy volunteers. Physostigmine 78-91 butyrylcholinesterase Homo sapiens 53-67 17658455-3 2007 With a view to enhancing the cholinergic drive on minor salivary glands, whilst at the same time minimising adverse systemic effects, the cholinesterase inhibitor physostigmine was therefore sprayed, in a fixed volume, onto the oral mucosa of seven healthy subjects. Physostigmine 163-176 butyrylcholinesterase Homo sapiens 138-152 16508314-4 2006 OBJECTIVE: We therefore administered low-dose physostigmine (PHYSO), a cholinesterase inhibitor, to normal, non-hormone-replaced, elderly women and men, to ascertain a potential sex difference in GH response. Physostigmine 46-59 butyrylcholinesterase Homo sapiens 71-85 12958052-1 2003 The cholinesterase inhibitor physostigmine (PHYS) was investigated in a double-blind, placebo-controlled, randomized, crossover trial of 10 male patients with moderate to severe obstructive sleep apnea. Physostigmine 29-42 butyrylcholinesterase Homo sapiens 4-18 12958052-1 2003 The cholinesterase inhibitor physostigmine (PHYS) was investigated in a double-blind, placebo-controlled, randomized, crossover trial of 10 male patients with moderate to severe obstructive sleep apnea. Physostigmine 44-48 butyrylcholinesterase Homo sapiens 4-18 12083745-2 2002 The earliest known ChE inhibitors, namely, physostigmine and tacrine, showed modest improvement in the cognitive function of AD patients. Physostigmine 43-56 butyrylcholinesterase Homo sapiens 19-22 12682768-4 2003 Pilocarpine supersensitivity was an indication against a lesion of the sphincter muscle and reduced response to cholinesterase inhibitors (physostigmine) pointed towards a postganglionic lesion. Physostigmine 139-152 butyrylcholinesterase Homo sapiens 112-126 12473087-3 2002 The cholinesterase inhibitor physostigmine, or a placebo control, were continuously infused into healthy young volunteers, during differential aversive conditioning whilst brain activity was measured using event-related functional magnetic resonance imaging (fMRI). Physostigmine 29-42 butyrylcholinesterase Homo sapiens 4-18 11927192-1 2002 We previously demonstrated that the reversible cholinesterase inhibitor, physostigmine (PHYSO), administered to normal young adult women and men (average age 35 years) at a dose that produced few or no side effects, resulted in a sex difference (sexual diergism) in hypothalamo-pituitary-adrenal cortical (HPA) axis responses: Plasma ACTH(1-39), cortisol, and arginine vasopressin (AVP) concentrations increased to a significantly greater extent in the men than in the women. Physostigmine 73-86 butyrylcholinesterase Homo sapiens 47-61 12073883-1 2002 An enzyme inhibition biosensor, developed in our laboratory and previously used for the analysis of compounds with anticholinesterase activity (e.g. physostigmine, neostigmine, pyridostigmine nicotine and organophosphorus compounds) has now been tested for the analysis of another recently synthesized cholinesterase inhibitor, i.e. eptastigmine. Physostigmine 149-162 butyrylcholinesterase Homo sapiens 119-133 11767272-0 2001 Stimulation of minor salivary glands by intraoral treatment with the cholinesterase inhibitor physostigmine in man. Physostigmine 94-107 butyrylcholinesterase Homo sapiens 69-83 11767272-2 2001 The aim of the present investigation was to stimulate the minor salivary glands by the topical application of the cholinesterase inhibitor physostigmine. Physostigmine 139-152 butyrylcholinesterase Homo sapiens 114-128 7636741-5 1995 The purpose of this study was to determine the selectivity of physostigmine, metrifonate, methanesulfonyl fluoride and tetrahydroaminoacridine (tacrine) toward AChE as compared with butyrylcholinesterase (BChE) in human cortex. Physostigmine 62-75 butyrylcholinesterase Homo sapiens 205-209 11697469-7 2001 This activity was strongly inhibited by physostigmine, a well-known inhibitor of cholinesterase. Physostigmine 40-53 butyrylcholinesterase Homo sapiens 81-95 11256231-2 2000 The carbamate derivatives physostigmine and rivastigmine needed preincubation to exhibit appropriate anti-ChE activity. Physostigmine 26-39 butyrylcholinesterase Homo sapiens 106-109 11256231-3 2000 The maximum ChE inhibition by physostigmine developed within 30-60 min, while the inhibitory effect of rivastigmine on AChE and BuChE activities reached its peak after 48 and 6 h, respectively. Physostigmine 30-43 butyrylcholinesterase Homo sapiens 12-15 11256231-4 2000 The order of inhibitory potency (IC50) towards AChE activity under optimal assay conditions for each ChE inhibitor was: physostigmine (0.67 nM) > rivastigmine (4.3 nM) > donepezil (6.7 nM) > TAK-147 (12 nM) > tacrine (77 nM) > ipidacrine (270 nM). Physostigmine 120-133 butyrylcholinesterase Homo sapiens 48-51 10643873-3 1999 To test the hypothesis of increased cholinergic sensitivity in major depression, physostigmine (PHYSO), a reversible cholinesterase inhibitor, was administered to patients and control subjects at a dose that elevated plasma ACTH, cortisol, and AVP concentrations but produced few or no side effects. Physostigmine 81-94 butyrylcholinesterase Homo sapiens 117-131 11249555-4 1999 It is structurally dissimilar from other established cholinesterase inhibitors, namely THA (an acridine compound) and the carbamates, physostigmine and rivastigmine and has a pharmacokinetic and tolerability profile distinct from these agents. Physostigmine 134-147 butyrylcholinesterase Homo sapiens 53-67 9880090-6 1998 Other cholinesterase inhibitors, such as galantamine (galanthamine), metrifonate, physostigmine, eptastigmine, are currently under clinical evaluation. Physostigmine 82-95 butyrylcholinesterase Homo sapiens 6-20 9689457-4 1998 The rCBF response abolished by scopolamine was recovered by the administration of physostigmine, a cholinesterase inhibitor in a dose-dependent manner. Physostigmine 82-95 butyrylcholinesterase Homo sapiens 99-113 8780856-3 1996 To address this question, we measured the plasma adrenocorticotropic hormone (ACTH), beta-endorphin-like immunoreactivity (beta E-LI), and cortisol responses to the cholinesterase inhibitor physostigmine in 10 healthy normal older subjects (age = 71 +/- 2 years) and 11 outpatients with probable AD (age = 72 +/- 2 years; Mini Mental State Exam score = 19 +/- 2). Physostigmine 190-203 butyrylcholinesterase Homo sapiens 165-179 7554703-10 1995 CONCLUSIONS: These results showed that, in cognitive responders, memory enhancement by physostigmine in Alzheimer"s disease is correlated directly to the magnitude of plasma cholinesterase inhibition. Physostigmine 87-100 butyrylcholinesterase Homo sapiens 174-188 11521162-10 2001 Inhibitors of cholinesterase (physostigmine, neostigmine; 3 microM) facilitated the efflux of acetylcholine about sixfold, and a combination of both (+)-tubocurarine (30 microM) and scopolamine (1 microM) halved the enhancing effect. Physostigmine 30-43 butyrylcholinesterase Homo sapiens 14-28 10192824-2 1999 Physostigmine (PHYSO), a reversible cholinesterase inhibitor, was administered to normal women and men at a dose that elevated plasma ACTH1-39, cortisol, and arginine vasopressin (AVP) concentrations but produced few or no side effects. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 36-50 10372954-1 1999 We have reported that physostigmine, a reversible cholinesterase inhibitor, enhances verbal memory in patients with Alzheimer disease (AD). Physostigmine 22-35 butyrylcholinesterase Homo sapiens 50-64 10637939-9 1999 Cholinergic drugs including cholinesterase inhibitors such as physostigmine, tacrine, velnacrine as well as the acetylcholine releaser linopiridine have been reported to increase the cerebral blood flow in AD patients both after acute and fairly short period of treatment. Physostigmine 62-75 butyrylcholinesterase Homo sapiens 28-42 8856831-3 1996 In addition, we evaluated whether the cholinesterase inhibitor, physostigmine, would prevent delta 9-THC-induced impairment of spatial memory. Physostigmine 64-77 butyrylcholinesterase Homo sapiens 38-52 7760120-9 1995 Ionophoresis of ACh into the neuropil depolarized FETi, as did the application of the cholinesterase inhibitor physostigmine. Physostigmine 111-124 butyrylcholinesterase Homo sapiens 86-100 7874590-1 1995 BACKGROUND: The purpose of this study was to determine the effects of normal human aging on the hypothalamic-pituitary-adrenocortical (HPA) axis response to the centrally active cholinesterase inhibitor physostigmine. Physostigmine 203-216 butyrylcholinesterase Homo sapiens 178-192 8749612-1 1995 Physostigmine, a reversible and nonselective cholinesterase inhibitor, administered by steady-state, continuous intravenous infusion to carefully selected subjects with mild-moderate Alzheimer disease, produced significant but modest improvement in memory in five of nine subjects. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 45-59 8749612-4 1995 Steady-state cholinesterase inhibition by physostigmine appears to produce sustained cognitive improvement in some subjects with Alzheimer disease without substantially altering its therapeutic index. Physostigmine 42-55 butyrylcholinesterase Homo sapiens 13-27 8848515-8 1995 In a second experiment, we evaluated the effects of scopolamine and mecamylamine on the AVP and NE responses to physostigmine, a cholinesterase inhibitor which stimulates AVP release into plasma through a non-osmolar central nervous system cholinergic mechanism. Physostigmine 112-125 butyrylcholinesterase Homo sapiens 129-143 7934317-1 1994 Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy). Physostigmine 6-19 butyrylcholinesterase Homo sapiens 41-55 7816881-5 1994 The cholinesterase inhibitors tacrine (THA) and, to a lesser extent, physostigmine (PHYSO) and amodiaquine (AMDQ), caused an upward shift in the frequency of the resting electrocortical activity, although scopolamine significantly slowed the activity below baseline levels. Physostigmine 69-82 butyrylcholinesterase Homo sapiens 4-18 7816881-5 1994 The cholinesterase inhibitors tacrine (THA) and, to a lesser extent, physostigmine (PHYSO) and amodiaquine (AMDQ), caused an upward shift in the frequency of the resting electrocortical activity, although scopolamine significantly slowed the activity below baseline levels. Physostigmine 84-89 butyrylcholinesterase Homo sapiens 4-18 7934317-1 1994 Heptylphysostigmine (HP) is a reversible cholinesterase (ChE) inhibitor with greater lipophilicity and longer inhibitory action than the parent compound, physostigmine (Phy). Physostigmine 6-19 butyrylcholinesterase Homo sapiens 57-60 8064320-10 1994 Maximum tolerated doses of the anti-cholinesterase, physostigmine, rather than tending to normalize abnormalities in these patients, further reduced cerebral metabolism (p < 0.01) and increased metabolism in thalamus in a pattern inversely correlated (p < 0.001) with that produced by scopolamine. Physostigmine 52-65 butyrylcholinesterase Homo sapiens 36-50 1967018-1 1990 The centrally active cholinesterase inhibitor physostigmine induces a behavioral syndrome which is thought to represent a model of spontaneous depression. Physostigmine 46-59 butyrylcholinesterase Homo sapiens 21-35 7907455-1 1993 Cholinesterase inhibitors, such as physostigmine and tacrine, have lately gained interest as potential drugs in the treatment of Alzheimer"s disease. Physostigmine 35-48 butyrylcholinesterase Homo sapiens 0-14 8248533-3 1993 The main disadvantages of the cholinesterase inhibitors used in clinical trials are the short duration of action in the case of physostigmine and the potential for liver toxicity seen with the aminoacridine derivatives. Physostigmine 128-141 butyrylcholinesterase Homo sapiens 30-44 1601960-1 1992 An analytical method was developed with sensitivity to detect clinically significant concentrations of heptylphysostigmine (HP), a new physostigmine derivative with potent and long-lasting inhibitory activity on cholinesterase. Physostigmine 109-122 butyrylcholinesterase Homo sapiens 212-226 1791534-1 1991 Physostigmine, an acetyl cholinesterase inhibitor, and arecoline, a muscarinic agonist, have been shown to improve Alzheimer presenile dementia in some patients when administered parenterally. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 25-39 1904998-3 1991 Studies in marmosets to assess the behavioural toxicology of physostigmine showed that the corresponding ED50 and ChE activity values were 34.3 (21.5-55.8) micrograms/kg and 66% respectively. Physostigmine 61-74 butyrylcholinesterase Homo sapiens 114-117 2683549-11 1989 This is achieved with physostigmine, a cholinesterase inhibitor able to easily cross the blood-brain barrier. Physostigmine 22-35 butyrylcholinesterase Homo sapiens 39-53 2570433-2 1989 These impairments can be reversed by appropriate agents such as the cholinesterase inhibitor physostigmine in the case of scopolamine or the benzodiazepine antagonist Ro 15-1788 in the case of lorazepam. Physostigmine 93-106 butyrylcholinesterase Homo sapiens 68-82 2497488-1 1989 The involvement of central and peripheral muscarinic cholinergic receptors in the behavioral effects of the cholinesterase inhibitor physostigmine was evaluated by comparing the ability of atropine and methylatropine to reverse the effects of physostigmine, the muscarinic agonist oxotremorine, or their quaternary analogs neostigmine and oxotremorine-M. Avoidance behavior was maintained under a schedule in which every lever press postponed delivery of electric shock for 20 s; shock occurred every 5 s in the absence of responding. Physostigmine 133-146 butyrylcholinesterase Homo sapiens 108-122 3074841-8 1988 Electrophysiological data showed that (-)physostigmine, among several reversible ChE inhibitors, showed greater potency in depressing both endplate current (EPC) peak amplitude and tau EPC. Physostigmine 41-54 butyrylcholinesterase Homo sapiens 81-84 3150807-1 1988 Inhibition of central nervous system cholinesterase with a single pulse of physostigmine induces a pronounced increase of blood flow in the neocortex, cingulate gyrus, claustrum, and amygdala. Physostigmine 75-88 butyrylcholinesterase Homo sapiens 37-51 3069749-4 1988 Physostigmine also significantly decreased plasma cholinesterase (ChE). Physostigmine 0-13 butyrylcholinesterase Homo sapiens 50-64 3069749-4 1988 Physostigmine also significantly decreased plasma cholinesterase (ChE). Physostigmine 0-13 butyrylcholinesterase Homo sapiens 66-69 3069749-5 1988 There was a significant positive correlation between the effects of physostigmine on increasing cortisol and decreasing ChE; there was no correlation between the increase in cortisol of cholinesterase inhibitor following neostigmine administration, but neither of these chemical parameters is related to the drug"s effects on cognitive functioning. Physostigmine 68-81 butyrylcholinesterase Homo sapiens 120-123 2821940-6 1987 Compounds containing C = O in the spacing moiety were active inhibitors of cholinesterase with some derivatives being nearly as active as physostigmine. Physostigmine 138-151 butyrylcholinesterase Homo sapiens 75-89 3809224-2 1986 However, these behaviors have also been induced or enhanced by physostigmine, a cholinesterase inhibitor. Physostigmine 63-76 butyrylcholinesterase Homo sapiens 80-94 3435078-1 1987 The histochemical distribution of cholinesterases in the cerebral cortex and their response to cholinesterase inhibitors such as physostigmine and tetrahydroaminoacridine (THA) were investigated in brains from patients with Alzheimer"s disease and control subjects. Physostigmine 129-142 butyrylcholinesterase Homo sapiens 34-48 3435078-3 1987 In keeping with their well-known cholinomimetic effects, physostigmine and THA effectively inhibited this cholinesterase activity. Physostigmine 57-70 butyrylcholinesterase Homo sapiens 106-120 3601008-4 1987 After intramuscular administration of physostigmine (500 micrograms/kg), the activity of cholinesterase in brain was maximally inhibited (76%) at 5 min and recovered to 50% at 40 min. Physostigmine 38-51 butyrylcholinesterase Homo sapiens 89-103 3601008-7 1987 With the exception of the cerebellum, there was a direct correlation between the concentration of physostigmine and inhibition of cholinesterase in a given area. Physostigmine 98-111 butyrylcholinesterase Homo sapiens 130-144 3524957-12 1986 Pharmacokinetic studies of the tertiary reversible cholinesterase inhibitor physostigmine, an important tool in experimental cholinergic neuropharmacology, are still in their initial stages. Physostigmine 76-89 butyrylcholinesterase Homo sapiens 51-65 2580948-5 1985 Physostigmine completely inhibits the hydrolysis of butyrylthiocholine by such purified cholinesterase preparations, but not their substance P-degrading activity. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 88-102 3980055-2 1985 In the current study we contrasted the cardiovascular effects of the centrally acting cholinesterase inhibitor physostigmine, which increases central and peripheral acetylcholine levels, with those of saline placebo and with those of the non-centrally acting cholinesterase inhibitor neostigmine, which only increases peripheral acetylcholine levels. Physostigmine 111-124 butyrylcholinesterase Homo sapiens 86-100 6516793-2 1984 It has been shown that systemically administered physostigmine, a cholinesterase inhibitor that penetrates the blood-brain barrier, causes barrier opening. Physostigmine 49-62 butyrylcholinesterase Homo sapiens 66-80 3797688-9 1986 The degree of memory improvement correlated with increasing cerebrospinal fluid cholinesterase inhibition suggesting that memory improvement is associated with entry of physostigmine into the brain. Physostigmine 169-182 butyrylcholinesterase Homo sapiens 80-94 3999598-7 1985 Local application of cholinesterase inhibitors in the form of Eserine, Prostigmin etc. Physostigmine 62-69 butyrylcholinesterase Homo sapiens 21-35 6511307-1 1984 The authors, with a spectrophotometric procedure, have evaluated the kinetic constants of physostigmine, a cholinesterase inhibitor which assumes an important function when the degeneration of cholinergic projections is observed. Physostigmine 90-103 butyrylcholinesterase Homo sapiens 107-121 6487203-3 1984 Physostigmine, a centrally active cholinesterase inhibitor which increases brain acetylcholine, was found to cause a motion sickness-like syndrome--in psychiatric patients and normals--including nausea, emesis, malaise, dysphoria, increases in serum ACTH, beta-endorphin, cortisol, and prolactin, Neostigmine, a non-centrally acting cholinesterase inhibitor, and saline placebo caused no such effects. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 34-48 6470148-3 1984 We stimulated central cholinergic activity in man by administering the cholinesterase inhibitor physostigmine to subjects pretreated with peripheral cholinergic blocking agents. Physostigmine 96-109 butyrylcholinesterase Homo sapiens 71-85 6487203-3 1984 Physostigmine, a centrally active cholinesterase inhibitor which increases brain acetylcholine, was found to cause a motion sickness-like syndrome--in psychiatric patients and normals--including nausea, emesis, malaise, dysphoria, increases in serum ACTH, beta-endorphin, cortisol, and prolactin, Neostigmine, a non-centrally acting cholinesterase inhibitor, and saline placebo caused no such effects. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 333-347 6747844-4 1984 Met-enkephalin had no effect on the release of ACh evoked by a 2-Hz stimulation when cholinesterase was inhibited by physostigmine. Physostigmine 117-130 butyrylcholinesterase Homo sapiens 85-99 7217205-10 1981 As in the normal SCG, physostigmine-resistant staining, caused by noncholinesterase enzymes plus the possible presence of very low concentrations of AChE or BuChE, was noted at external mitochondrial membranes, elements of the endoplasmic reticulum of neurites and Schwann cells, and also in lysosomes. Physostigmine 22-35 butyrylcholinesterase Homo sapiens 157-162 33317802-2 2021 In addition, the anti-cholinesterase drug physostigmine that increases synaptic acetylcholine concentrations has anti-inflammatory effects. Physostigmine 42-55 butyrylcholinesterase Homo sapiens 22-36 32729530-2 2020 Among several drugs, we designed the device for evaluating the efficacy of compounds (e.g. physostigmine, rivastigmine, donepezil) which are able to inhibit in a reversible way the cholinesterase enzyme. Physostigmine 91-104 butyrylcholinesterase Homo sapiens 181-195 31517530-2 2019 The structural properties and binding interactions of the AD drug physostigmine (-)-phy, and its analogues (-)-hex and (-)-phe and (+)-phe, were examined, as well as their impact on the conformational changes of two different AD target enzymes AChE and BChE. Physostigmine 66-79 butyrylcholinesterase Homo sapiens 253-257 26589572-3 2016 Cholinesterase inhibitors, such as physostigmine, are effective but widespread use has been limited by concerns about safety, optimal dosing and variable supply. Physostigmine 35-48 butyrylcholinesterase Homo sapiens 0-14 24236981-2 2013 In this sense, many alkaloids isolated from natural sources, such as physostigmine, have been long recognized as acetyl- and butyrylcholinesterase (BChE) inhibitors. Physostigmine 69-82 butyrylcholinesterase Homo sapiens 148-152 6143326-3 1984 The study reported here examined the effects of the cholinesterase inhibitor physostigmine, and several other cholinergic and anticholinergic drugs, on stimulant-induced behavior. Physostigmine 77-90 butyrylcholinesterase Homo sapiens 52-66 6347034-6 1983 The decrease in intrusions was strongly correlated with increasing inhibition of cholinesterase activity in cerebrospinal fluid, suggesting that the degree of improvement in the patient"s memory was related to the amount of physostigmine that reached the brain. Physostigmine 224-237 butyrylcholinesterase Homo sapiens 81-95 6840979-2 1983 The individual physostigmine dose was assessed by means of serum cholinesterase activity monitoring. Physostigmine 15-28 butyrylcholinesterase Homo sapiens 65-79 6752738-1 1982 Ten patients with clinically diagnosed Alzheimer"s disease were given tests of recognition memory while receiving placebo or physostigmine, a cholinesterase inhibitor, given intravenously over 30 min. Physostigmine 125-138 butyrylcholinesterase Homo sapiens 142-156 7135153-2 1982 If these neuronal effects are associated with CNS depression, then administration of a cholinesterase inhibitor (physostigmine) with ethanol should result in antagonism of this CNS depression. Physostigmine 113-126 butyrylcholinesterase Homo sapiens 87-101 7298772-0 1981 Quantitative determination of the cholinesterase inhibitor physostigmine in brain tissue samples using reversed-phase high-performance liquid chromatography. Physostigmine 59-72 butyrylcholinesterase Homo sapiens 34-48 7188667-1 1980 Patients undergoing dental extraction under intravenous diazepam sedation were studied to determine whether physostigmine, a cholinesterase inhibitor, reverses diazepam-induced sedation. Physostigmine 108-121 butyrylcholinesterase Homo sapiens 125-139 445230-3 1979 It was found that stimulation induced vasoconstrictor responses which were enhanced by physostigmine, a cholinesterase inhibitor, and blocked by atropine. Physostigmine 87-100 butyrylcholinesterase Homo sapiens 104-118 30564-2 1978 Physostigmine is known to reverse the central muscarinic anticholinergic manifestations by inhibition of the enzyme cholinesterase. Physostigmine 0-13 butyrylcholinesterase Homo sapiens 116-130 203742-7 1977 Of great significance in ocular myasthenia is the local application of cholinesterase inhibitors like Eserine, Prostigmin or Phospholine Iodide. Physostigmine 102-109 butyrylcholinesterase Homo sapiens 71-85 4343315-2 1972 Studies involving the electrophoretic administration of antagonists of ACh (atropine, DHbetaE) and cholinesterase inhibitors (neostigmine, physostigmine) to MGN neurones indicate that ACh is an excitatory transmitter in the feline MGN, most probably released from fibres which originate in or traverse the mesencephalon.2. Physostigmine 139-152 butyrylcholinesterase Homo sapiens 99-113 5315359-8 1971 A unique cholinesterase was found in motor end-plates of cricket muscle, which hydrolyses acetylthiocholine and which was inhibited by physostigmine. Physostigmine 135-148 butyrylcholinesterase Homo sapiens 9-23 13525672-7 1958 The inhibition of sodium extrusion by physostigmine was correlated with the inhibition of the intracellular cholinesterase. Physostigmine 38-51 butyrylcholinesterase Homo sapiens 108-122 19873399-0 1944 THE MECHANISM OF ENZYME-INHIBITOR-SUBSTRATE REACTIONS : ILLUSTRATED BY THE CHOLINESTERASE-PHYSOSTIGMINE-ACETYLCHOLINE SYSTEM. Physostigmine 90-103 butyrylcholinesterase Homo sapiens 75-89 19873399-10 1944 The inhibition of cholinesterase by physostigmine is competitive. Physostigmine 36-49 butyrylcholinesterase Homo sapiens 18-32 19873399-11 1944 A single molecule of physostigmine or acetylcholine combines with one center of cholinesterase-n = 1; and the mechanism n = 2 has been. Physostigmine 21-34 butyrylcholinesterase Homo sapiens 80-94 19873399-23 1944 The destruction of physostigmine or acetylcholine by cholinesterase follows the predicted curve; k(D) for the destruction of physostigmine is found to be > 0.00182; k(D) for acetylcholine destruction is > 3500. Physostigmine 19-32 butyrylcholinesterase Homo sapiens 53-67 19873399-23 1944 The destruction of physostigmine or acetylcholine by cholinesterase follows the predicted curve; k(D) for the destruction of physostigmine is found to be > 0.00182; k(D) for acetylcholine destruction is > 3500. Physostigmine 125-138 butyrylcholinesterase Homo sapiens 53-67 19873367-0 1943 ZONE BEHAVIOR OF ENZYMES : ILLUSTRATED BY THE EFFECT OF DISSOCIATION CONSTANT AND DILUTION ON THE SYSTEM CHOLINESTERASE-PHYSOSTIGMINE. Physostigmine 120-133 butyrylcholinesterase Homo sapiens 105-119 30245349-5 2018 Acarbose was used as a reference standard for alpha-glucosidase inhibition while eserine for AChE and BChE inhibition. Physostigmine 81-88 butyrylcholinesterase Homo sapiens 102-106 26772968-6 2016 In vitro, the enzyme activity of human AChE and BChE was inhibited in a concentration-dependent manner until a residual activity of 4-6% for AChE and 20-30% for BChE (IC 50 human AChE: 0.117 +- 0.007 muM physostigmine, 0.062 +- 0.003 muM neostigmine; IC 50 human BChE: 0.373 +- 0.089 muM neostigmine; 0.059 +- 0.012 muM physostigmine). Physostigmine 204-217 butyrylcholinesterase Homo sapiens 48-52 26772968-6 2016 In vitro, the enzyme activity of human AChE and BChE was inhibited in a concentration-dependent manner until a residual activity of 4-6% for AChE and 20-30% for BChE (IC 50 human AChE: 0.117 +- 0.007 muM physostigmine, 0.062 +- 0.003 muM neostigmine; IC 50 human BChE: 0.373 +- 0.089 muM neostigmine; 0.059 +- 0.012 muM physostigmine). Physostigmine 320-333 butyrylcholinesterase Homo sapiens 48-52 26318401-2 2015 All analogs exhibited varied butyrylcholinesterase inhibitory activity with IC50 value ranging between 1.59+-0.01 and 389.25+-1.75muM when compared with the standard eserine (IC50, 0.85+-0.0001muM). Physostigmine 166-173 butyrylcholinesterase Homo sapiens 29-50